[go: up one dir, main page]

AR126166A1 - COMBINATION OF AN ERK INHIBITOR AND A KRAS INHIBITOR AND USES OF THESE - Google Patents

COMBINATION OF AN ERK INHIBITOR AND A KRAS INHIBITOR AND USES OF THESE

Info

Publication number
AR126166A1
AR126166A1 ARP220101591A ARP220101591A AR126166A1 AR 126166 A1 AR126166 A1 AR 126166A1 AR P220101591 A ARP220101591 A AR P220101591A AR P220101591 A ARP220101591 A AR P220101591A AR 126166 A1 AR126166 A1 AR 126166A1
Authority
AR
Argentina
Prior art keywords
inhibitor
kras
combination
erk
pharmaceutically acceptable
Prior art date
Application number
ARP220101591A
Other languages
Spanish (es)
Inventor
Bing Hou
Jian Wang
Bo Shan
Xingxing Wang
Yun Liu
Peng Chen
Hui Yuwen
Bin Jiang
Jay Mei
Original Assignee
Antengene Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antengene Discovery Ltd filed Critical Antengene Discovery Ltd
Publication of AR126166A1 publication Critical patent/AR126166A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente divulgación en general se refiere a la combinación de un inhibidor de ERK y un inhibidor de KRAS y usos de estos. Reivindicación 51: Una composición farmacéutica caracterizada porque comprende un inhibidor de KRAS o una sal farmacéuticamente aceptable de este, y un inhibidor de ERK o una sal farmacéuticamente aceptable de este.The present disclosure generally relates to the combination of an ERK inhibitor and a KRAS inhibitor and uses thereof. Claim 51: A pharmaceutical composition characterized in that it comprises a KRAS inhibitor or a pharmaceutically acceptable salt thereof, and an ERK inhibitor or a pharmaceutically acceptable salt thereof.

ARP220101591A 2021-06-18 2022-06-16 COMBINATION OF AN ERK INHIBITOR AND A KRAS INHIBITOR AND USES OF THESE AR126166A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2021100892 2021-06-18
CN2022095820 2022-05-28

Publications (1)

Publication Number Publication Date
AR126166A1 true AR126166A1 (en) 2023-09-27

Family

ID=84526853

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220101591A AR126166A1 (en) 2021-06-18 2022-06-16 COMBINATION OF AN ERK INHIBITOR AND A KRAS INHIBITOR AND USES OF THESE

Country Status (4)

Country Link
CN (1) CN117529321A (en)
AR (1) AR126166A1 (en)
TW (1) TW202317130A (en)
WO (1) WO2022262797A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023081840A1 (en) 2021-11-05 2023-05-11 Frontier Medicines Corporation Kras g12c inhibitors
WO2023137223A1 (en) * 2022-01-17 2023-07-20 Newave Pharmaceutical Inc. Pan-kras inhibitors and uses thereof
TW202508595A (en) * 2023-05-04 2025-03-01 美商銳新醫藥公司 Combination therapy for a ras related disease or disorder

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI730012B (en) * 2015-11-09 2021-06-11 瑞典商阿斯特捷利康公司 Chemical compounds
EP3269365A1 (en) * 2016-07-14 2018-01-17 Friedrich-Alexander-Universität Erlangen-Nürnberg Kras inhibitor for use in treating cancer
JOP20190272A1 (en) * 2017-05-22 2019-11-21 Amgen Inc Kras g12c inhibitors and methods of using the same
EA202091186A1 (en) * 2017-11-15 2020-10-01 Мирати Терапьютикс, Инк. KRas G12C INHIBITORS
CN112830928A (en) * 2019-11-22 2021-05-25 四川海思科制药有限公司 Pyrimido-cyclic derivative and application thereof in medicine
IL298670A (en) * 2020-06-04 2023-01-01 Antengene Discovery Ltd Inhibitors of kras g12c protein and uses thereof

Also Published As

Publication number Publication date
WO2022262797A1 (en) 2022-12-22
CN117529321A (en) 2024-02-06
TW202317130A (en) 2023-05-01

Similar Documents

Publication Publication Date Title
AR126166A1 (en) COMBINATION OF AN ERK INHIBITOR AND A KRAS INHIBITOR AND USES OF THESE
CL2023000767A1 (en) Methods to reduce the risk of cardiovascular events in a subject.
CA3148745A1 (en) Kras g12d inhibitors
CY1126067T1 (en) FUSIONED PYROLINES THAT ACT AS UBIQUITIN-SPECIFIC PROTEASE 30 (USP30) INHIBITORS
MX2020013116A (en) Novel salts and crystals.
CO5600999A2 (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE INHIBITORS OF VALSARTAN AND NEUTRAL ENDOPEPTIDASE
AR054805A1 (en) TOPICAL COMPOSITIONS FOR SKIN TREATMENT
UA89220C2 (en) METHOD OF TREATMENT OF HIV / AIDS BY INJURY WITHOUT FOOD OR UNDER CONDITIONS OF STORAGE OF SOLID PHARMACEUTICAL DOSAGE INHIBITOR INHIBITOR
CO6331425A2 (en) COMPOSITIONS THAT INCLUDE N- (3,4-DIFLUORO-2- (2-FLUORO-4-IODOFENILAMINO) 6-METOXIFENIL) -1- (2,3-DIHYDROXIPROXIPROPIL) CICLOPROPAN-1-SULFAMIDA
JOP20200336A1 (en) Methods for the administration of certain vmat2 inhibitors
UY26825A1 (en) COMPOSTION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLOXOACETIC PIPERAZINE DERIVATIVES
PH12019550249A1 (en) Solid compositions for oral administration
CO2024006819A2 (en) Compositions and treatments with nirogacestat
ES2183817T3 (en) METAZOAR PARASATIS PROTEASES INIBIDORS.
MX2025003008A (en) Dosing regimen for treating pku with a piperidine inhibitor of slc6a19 function
AR117600A1 (en) FORMULATIONS OF AN AXL / MER INHIBITOR
MXPA04001397A (en) METHOD AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF PAIN AND INFLAMMATION WITH A SELECTIVE INHIBITOR OF CYCLLOXYGENASA-2 AND CONDROITIN SULFATE.
AR084216A1 (en) COMPOSITIONS AND METHODS TO TREAT CANCER USING A PI3K INHIBITOR AND MEK INHIBITOR, KIT
MX2019003039A (en) PROLONGED RELIEF DOSAGE FORM.
CL2021002107A1 (en) Triamterene or nolatrexed for use in the treatment of phenylketonuria.
EA200300639A1 (en) USE OF SARP-1 FOR THE TREATMENT AND / OR PREVENTION OF SCLERODERMIA
MX2022005388A (en) PYRROLIDINE AND PIPERIDINE COMPOUNDS.
MY205335A (en) Compositions and methods for treating severe constipation
MX2023014898A (en) ADVANTAGEOUS ANTI-HCV COMBINED THERAPY.
CL2022002317A1 (en) Methods of treating primary progressive multiple sclerosis using a bruton tyrosine kinase inhibitor.

Legal Events

Date Code Title Description
FB Suspension of granting procedure